abstract |
The present invention relates to the technical field of biomedicine, particularly to a selective dihydropyrrolopyrimidine JAK2 inhibitor or a pharmaceutically acceptable salt thereof. Compared with the prior art, the pyrrolopyrimidine compounds, stereoisomers and pharmaceutically acceptable salts thereof provided by the present invention exhibit better inhibitory activity for Janus Kinase and significantly better selectivity for JAK2 inhibitory targets. In addition, the preferred compounds of the present invention exhibit good pharmacokinetic properties and have the potential to be developed as selective JAK2 inhibitors. |